Theravance Biopharma (TBPH) Competitors $11.22 -0.09 (-0.80%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TBPH vs. NAMS, RXRX, BCRX, INDV, SPRY, CNTA, EVO, OCUL, GRDN, and AUPHShould you be buying Theravance Biopharma stock or one of its competitors? The main competitors of Theravance Biopharma include NewAmsterdam Pharma (NAMS), Recursion Pharmaceuticals (RXRX), BioCryst Pharmaceuticals (BCRX), Indivior (INDV), ARS Pharmaceuticals (SPRY), Centessa Pharmaceuticals (CNTA), Evotec (EVO), Ocular Therapeutix (OCUL), Guardian Pharmacy Services (GRDN), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "med - drugs" industry. Theravance Biopharma vs. Its Competitors NewAmsterdam Pharma Recursion Pharmaceuticals BioCryst Pharmaceuticals Indivior ARS Pharmaceuticals Centessa Pharmaceuticals Evotec Ocular Therapeutix Guardian Pharmacy Services Aurinia Pharmaceuticals Theravance Biopharma (NASDAQ:TBPH) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk. Which has more volatility and risk, TBPH or NAMS? Theravance Biopharma has a beta of -0.02, meaning that its share price is 102% less volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of -0.03, meaning that its share price is 103% less volatile than the S&P 500. Is TBPH or NAMS more profitable? Theravance Biopharma has a net margin of -89.38% compared to NewAmsterdam Pharma's net margin of -397.45%. Theravance Biopharma's return on equity of -32.37% beat NewAmsterdam Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Theravance Biopharma-89.38% -32.37% -16.48% NewAmsterdam Pharma -397.45%-37.34%-33.45% Which has better earnings and valuation, TBPH or NAMS? Theravance Biopharma has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTheravance Biopharma$64.38M8.71-$56.42M-$1.18-9.51NewAmsterdam Pharma$47.14M47.68-$241.60M-$1.88-10.65 Does the media prefer TBPH or NAMS? In the previous week, NewAmsterdam Pharma had 2 more articles in the media than Theravance Biopharma. MarketBeat recorded 2 mentions for NewAmsterdam Pharma and 0 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 0.00 equaled NewAmsterdam Pharma'saverage media sentiment score. Company Overall Sentiment Theravance Biopharma Neutral NewAmsterdam Pharma Neutral Do analysts recommend TBPH or NAMS? Theravance Biopharma currently has a consensus target price of $16.60, suggesting a potential upside of 47.95%. NewAmsterdam Pharma has a consensus target price of $42.89, suggesting a potential upside of 114.23%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Theravance Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Theravance Biopharma 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.67NewAmsterdam Pharma 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders hold more shares of TBPH or NAMS? 99.1% of Theravance Biopharma shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 6.9% of Theravance Biopharma shares are held by company insiders. Comparatively, 20.8% of NewAmsterdam Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryTheravance Biopharma beats NewAmsterdam Pharma on 10 of the 16 factors compared between the two stocks. Get Theravance Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TBPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TBPH vs. The Competition Export to ExcelMetricTheravance BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$561M$2.37B$5.47B$8.92BDividend YieldN/A1.78%5.24%4.04%P/E Ratio-9.518.9227.0520.14Price / Sales8.71501.68380.7693.83Price / CashN/A21.7726.2128.59Price / Book3.144.528.005.58Net Income-$56.42M$31.26M$3.16B$248.40M7 Day Performance2.84%6.11%3.84%6.13%1 Month Performance-0.27%5.75%3.04%7.78%1 Year Performance26.92%1.24%34.26%20.95% Theravance Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TBPHTheravance Biopharma1.4661 of 5 stars$11.22-0.8%$16.60+48.0%+29.1%$561M$64.38M-9.51110NAMSNewAmsterdam Pharma2.2597 of 5 stars$18.11-2.5%$42.89+136.8%-2.7%$2.08B$45.56M-9.634Positive NewsAnalyst UpgradeRXRXRecursion Pharmaceuticals1.9374 of 5 stars$5.06+0.6%$7.00+38.3%-32.7%$2.04B$58.84M-2.86400Trending NewsAnalyst ForecastBCRXBioCryst Pharmaceuticals4.4604 of 5 stars$8.96-4.3%$16.89+88.5%+34.4%$1.96B$450.71M-34.46530INDVIndivior2.6328 of 5 stars$14.74+5.7%$17.00+15.3%+3.0%$1.92B$1.19B-47.551,051High Trading VolumeSPRYARS Pharmaceuticals3.2379 of 5 stars$17.45-4.1%$31.00+77.7%+87.8%$1.79B$89.15M-109.0690Positive NewsHigh Trading VolumeCNTACentessa Pharmaceuticals3.1689 of 5 stars$13.14+0.1%$27.89+112.2%+55.8%$1.75B$6.85M-7.26200EVOEvotec1.6999 of 5 stars$4.20+1.0%$5.93+41.3%-21.1%$1.48B$862.40M0.004,827Positive NewsOCULOcular Therapeutix3.9399 of 5 stars$9.28+0.7%$17.33+86.8%+44.1%$1.47B$63.72M-8.07230Gap UpGRDNGuardian Pharmacy Services1.3876 of 5 stars$21.39+0.0%$25.67+20.0%N/A$1.35B$1.23B0.003,400High Trading VolumeAUPHAurinia Pharmaceuticals2.5626 of 5 stars$8.47-2.0%$11.50+35.8%+33.2%$1.17B$235.13M30.25300 Related Companies and Tools Related Companies NAMS Alternatives RXRX Alternatives BCRX Alternatives INDV Alternatives SPRY Alternatives CNTA Alternatives EVO Alternatives OCUL Alternatives GRDN Alternatives AUPH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TBPH) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theravance Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theravance Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
